An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Isotretinoin (Primary)
- Indications Nodulocystic acne
- Focus Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
- 18 Apr 2017 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2015 New trial record